RT Journal Article
SR Electronic
T1 Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 619
OP 626
DO 10.1136/jclinpath-2015-203418
VO 69
IS 7
A1 Bertram, Stefanie
A1 Padden, Juliet
A1 Kälsch, Julia
A1 Ahrens, Maike
A1 Pott, Leona
A1 Canbay, Ali
A1 Weber, Frank
A1 Fingas, Christian
A1 Hoffmann, Andreas C
A1 Vietor, Antonie
A1 Schlaak, Joerg F
A1 Eisenacher, Martin
A1 Reis, Henning
A1 Sitek, Barbara
A1 Baba, Hideo A
YR 2016
UL http://jcp.bmj.com/content/69/7/619.abstract
AB Aims The distinction between intrahepatic cholangiocarcinoma (ICC) and benign bile duct lesions can be challenging. Using our previously identified potential biomarkers for ICC, we examined whether these are useful for the differential diagnosis of ICC, bile duct adenoma and reactive bile duct proliferations in an immunohistochemical approach and identified a diagnostic marker panel including known biomarkers.Methods Subjects included samples from 77 patients with ICC, 33 patients with bile duct adenoma and 47 patients with ductular reactions in liver cirrhosis. Our previously identified biomarkers (stress-induced phosphoprotein 1 (STIP1), SerpinH1, 14-3-3Sigma) were tested immunohistochemically following comparison with candidates from the literature (cluster of differentiation 56, heat shock protein (HSP)27, HSP70, B-cell-lymphoma2, p53, ki67).Results The expression of SerpinH1 and 14-3-3Sigma was significantly higher in ICC than in bile duct adenomas and ductular reactions (p<0.05), whereas STIP1 expression was significantly higher (p<0.05) in ICC than in ductular reactions, but the difference to the bile duct adenoma group was not significant. A panel of the biomarker SerpinH1, 14-3-3Sigma and ki67 (≥2 marker positive) showed a high diagnostic accuracy (sensitivity 87.8%, specificity 95.9%, accuracy 91.8%) in the differential diagnosis of ICC versus non-malignant bile duct lesions.Conclusions This suggests that 14-3-3Sigma and SerpinH1 may be useful in the differential diagnosis of malignant, benign and reactive bile duct lesions in addition to ki67 where a cut-off of >5% might be used for the distinction of malignant and non-malignant lesions.